IN192874B - - Google Patents

Info

Publication number
IN192874B
IN192874B IN601DE1997A IN192874B IN 192874 B IN192874 B IN 192874B IN 601DE1997 A IN601DE1997 A IN 601DE1997A IN 192874 B IN192874 B IN 192874B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Paul Perry Tamburini
Gary Davis
Katherine Anne Delaria
Christopher Ward Marlor
Daniel Karl Muller
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Priority to IN39DE2001 priority Critical patent/IN189770B/en
Publication of IN192874B publication Critical patent/IN192874B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
IN601DE1997 1996-03-11 1997-03-11 IN192874B (en:Method)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN39DE2001 IN189770B (en:Method) 1996-03-11 2001-01-19

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1310696P 1996-03-11 1996-03-11
US1979396P 1996-06-14 1996-06-14
US72525196A 1996-10-04 1996-10-04

Publications (1)

Publication Number Publication Date
IN192874B true IN192874B (en:Method) 2004-05-29

Family

ID=27359773

Family Applications (1)

Application Number Title Priority Date Filing Date
IN601DE1997 IN192874B (en:Method) 1996-03-11 1997-03-11

Country Status (27)

Country Link
US (3) US6583108B1 (en:Method)
EP (1) EP0891426B1 (en:Method)
JP (2) JP3469584B2 (en:Method)
KR (1) KR100356956B1 (en:Method)
AR (3) AR006188A1 (en:Method)
AT (1) ATE328083T1 (en:Method)
AU (1) AU716923B2 (en:Method)
BR (1) BR9708021A (en:Method)
CA (1) CA2247888A1 (en:Method)
CO (1) CO4600683A1 (en:Method)
DE (1) DE69735996T2 (en:Method)
DK (1) DK0891426T3 (en:Method)
ES (1) ES2263174T3 (en:Method)
HR (1) HRP970144B1 (en:Method)
HU (1) HU226419B1 (en:Method)
ID (1) ID16224A (en:Method)
IL (1) IL126115A (en:Method)
IN (1) IN192874B (en:Method)
MY (1) MY120693A (en:Method)
NZ (1) NZ331540A (en:Method)
PA (1) PA8426301A1 (en:Method)
PL (1) PL188387B1 (en:Method)
PT (1) PT891426E (en:Method)
SV (1) SV1997000018A (en:Method)
TR (1) TR199801794T2 (en:Method)
WO (1) WO1997033996A2 (en:Method)
YU (1) YU8997A (en:Method)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
EP0758682B1 (en) * 1995-07-24 2004-05-12 Mitsubishi Chemical Corporation Hepatocyte growth factor activator inhibitor
DK0891426T3 (da) 1996-03-11 2006-10-02 Bayer Corp Humant bikunin
EP1005551A2 (en) 1997-01-31 2000-06-07 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
AU758832B2 (en) * 1998-12-22 2003-04-03 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
WO2000051624A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Methods and compositions useful in inhibiting apoptosis
US6489308B1 (en) 1999-03-05 2002-12-03 Trustees Of University Of Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions
US20040235715A1 (en) * 1999-11-12 2004-11-25 Bayer Corporation Method of producing glycosylated bikunin
IL140994A (en) * 2000-05-15 2005-12-18 Bayer Ag Urinary trypsin inhibitor assay containing a chelating agent
IL140993A0 (en) 2000-05-15 2002-02-10 Bayer Ag Trypsin substrate and diagnostic device, and method of using same
US6955921B2 (en) * 2001-04-30 2005-10-18 Bayer Corporation Trypsin substrate and diagnostic device, and method of using same
WO2003040330A2 (en) * 2001-11-05 2003-05-15 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
CA2516056C (en) 2003-01-06 2012-05-29 Angiochem Inc. Aprotinin and analogs as carriers across the blood-brain barrier
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
DK2520654T3 (en) 2003-08-26 2017-05-01 Univ Colorado Regents Inhibitors of serine protease activity and their use in methods and compositions for the treatment of bacterial infections
DE602004025380D1 (de) * 2003-10-10 2010-03-18 Multicell Technologies Inc Immortalisierte hepatozyten
EP1675874A1 (en) * 2003-10-16 2006-07-05 Bayer HealthCare LLC Monoclonal antibodies for detection of urinary trypsin inhibitors
EP1586587A1 (en) * 2004-04-16 2005-10-19 Exonhit Therapeutics SA Compositions and methods for detecting angiogenesis
EP1810185A4 (en) 2004-06-04 2010-01-06 Therasense Inc DIABETES SUPPLY HOST CLIENT ARCHITECTURE AND DATA MANAGEMENT SYSTEM
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US7902156B2 (en) * 2005-02-18 2011-03-08 Angiochem Inc. Aprotinin polypeptides for transporting a compound across the blood-brain barrier
WO2007011693A2 (en) * 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
EP1907009A4 (en) 2005-07-15 2009-09-02 Angiochem Inc USE OF APROTININ POLYPEPTIDES AS CARRIER IN PHARMACEUTICAL CONJUGATES
US8093017B2 (en) 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
CA2635589C (en) * 2005-12-29 2017-01-17 Dyax Corp. Protease inhibition
CA2663545A1 (en) * 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof
WO2008058167A2 (en) * 2006-11-07 2008-05-15 Case Western Reserve University Method for treating disorders associated with complement activation
WO2008077478A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP2170932A4 (en) * 2007-06-20 2012-10-10 Phylogica Ltd COMPOSITIONS AND APPLICATIONS THEREOF IN THE TREATMENT OF ACUTE ATOMIC SYNDROME (ARDS) AND ASSOCIATED CLINICAL ILLNESSES
CA2696208A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
US8710013B2 (en) * 2008-04-18 2014-04-29 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
JP2012505637A (ja) 2008-10-15 2012-03-08 アンジオケム，インコーポレーテッド Ｇｌｐ−１アゴニストのコンジュゲート及びその使用
US8828925B2 (en) 2008-10-15 2014-09-09 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
BRPI0922689A2 (pt) 2008-12-05 2018-11-06 Angiochem Inc. conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos
EP2373789A4 (en) 2008-12-17 2012-08-29 Angiochem Inc MEMBRANTYP-1 MATRIX METALLOPROTEINASE INHIBITORS AND THEIR USE
CA2744235A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
WO2010121379A1 (en) 2009-04-20 2010-10-28 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
IN2012DN00248A (en:Method) 2009-07-02 2015-05-01 Angiochem Inc
HUE039605T2 (hu) 2010-01-06 2019-01-28 Dyax Corp Plazma kallikreint kötõ proteinek
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
CA2823776A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
EP2723370A4 (en) 2011-06-24 2015-06-03 Univ Colorado Regents COMPOSITIONS, PROCESS AND USE OF ALPHA-1-ANTITRYPHIN FUSION MOLECULES
JP2015504675A (ja) 2012-01-10 2015-02-16 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１アンチトリプシン融合分子の組成物、方法、及び使用
EP2885318A4 (en) 2012-08-14 2016-03-30 Angiochem Inc PEPTIDE DENDRIMER CONJUGATES AND ITS USES
NZ760789A (en) 2014-02-24 2023-03-31 Takeda Pharmaceuticals Co Uti fusion proteins
JP6719384B2 (ja) 2014-03-27 2020-07-15 ダイアックス コーポレーション 糖尿病黄斑浮腫の治療のための組成物および方法
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
IL259691B2 (en) 2015-12-11 2024-08-01 Dyax Corp Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
BR112022017718A2 (pt) 2020-03-05 2022-11-16 Diamedica Usa Inc Polipeptídeos de ulinastatina

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
DE59007737D1 (de) 1989-05-13 1995-01-05 Bayer Ag Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel.
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
ES2086521T3 (es) 1990-01-25 1996-07-01 Univ Washington Proteina hibrida laci-factor x.
DE573603T1 (de) 1991-03-01 1999-05-06 Dyax Corp., Cambridge, Mass. Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g.
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
CA2139945A1 (en) 1992-07-13 1994-01-20 Ignace Lasters Bovine pancreatic trypsin inhibitor derived inhibitors of factor xa
US5436153A (en) 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
EP0740702A1 (en) 1992-12-02 1996-11-06 Zymogenetics, Inc. Novel human amyloid protein precursor homologue and kunitz-type inhibitors
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5795865A (en) 1994-01-11 1998-08-18 Dyax Corp. Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
EP0737207B1 (en) 1994-01-11 2004-09-22 Dyax Corporation Inhibitors of human plasmin derived from the kunitz domains
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
WO1996003503A1 (en) 1994-07-21 1996-02-08 The Green Cross Corporation Process for producing urinary trypsin inhibitor and domains thereof, novel polypeptide related to the both, and process for producing the polypeptide
US5541228A (en) * 1994-10-14 1996-07-30 Bristol-Myers Squibb Co. Melatonergic agents
CA2220497A1 (en) 1995-05-08 1996-11-14 Scios, Inc. Kunitz type protease inhibitors
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
EP0758682B1 (en) * 1995-07-24 2004-05-12 Mitsubishi Chemical Corporation Hepatocyte growth factor activator inhibitor
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
DK0891426T3 (da) 1996-03-11 2006-10-02 Bayer Corp Humant bikunin
EP1005551A2 (en) 1997-01-31 2000-06-07 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity

Also Published As

Publication number Publication date
CA2247888A1 (en) 1997-09-18
DE69735996D1 (de) 2006-07-06
AR058982A1 (es) 2008-03-05
MY120693A (en) 2005-11-30
ATE328083T1 (de) 2006-06-15
NZ331540A (en) 1999-10-28
AU2207797A (en) 1997-10-01
IL126115A0 (en) 1999-05-09
EP0891426A2 (en) 1999-01-20
SV1997000018A (es) 1999-01-14
JP2004000208A (ja) 2004-01-08
KR19990087697A (ko) 1999-12-27
DK0891426T3 (da) 2006-10-02
US6583108B1 (en) 2003-06-24
US20060172946A1 (en) 2006-08-03
BR9708021A (pt) 1999-07-27
US20030194398A1 (en) 2003-10-16
EP0891426B1 (en) 2006-05-31
AR006188A1 (es) 1999-08-11
US7019123B2 (en) 2006-03-28
HU226419B1 (en) 2008-12-29
AU716923B2 (en) 2000-03-09
AR053063A2 (es) 2007-04-18
PL328822A1 (en) 1999-02-15
ES2263174T3 (es) 2006-12-01
JP2001521367A (ja) 2001-11-06
PL188387B1 (pl) 2005-01-31
YU8997A (sh) 1999-09-27
DE69735996T2 (de) 2007-02-15
CO4600683A1 (es) 1998-05-08
WO1997033996A3 (en) 1997-11-13
US7452859B2 (en) 2008-11-18
HUP9902698A2 (hu) 1999-11-29
TR199801794T2 (xx) 2000-07-21
ID16224A (id) 1997-09-11
PA8426301A1 (es) 2000-05-24
HRP970144A2 (en) 1998-04-30
KR100356956B1 (ko) 2003-03-15
HRP970144B1 (en) 2004-10-31
WO1997033996A2 (en) 1997-09-18
JP3469584B2 (ja) 2003-11-25
HUP9902698A3 (en) 2001-06-28
IL126115A (en) 2007-03-08
PT891426E (pt) 2006-10-31

Similar Documents

Publication Publication Date Title
AR026659A2 (en:Method)
BRPI9713914B8 (en:Method)
BR7600721U (en:Method)
BR7601346U (en:Method)
BR9603859A (en:Method)
CN3039060S (en:Method)
CN3039213S (en:Method)
CN3040024S (en:Method)
CN3040367S (en:Method)
CN3040543S (en:Method)
CN3040550S (en:Method)
CN3040805S (en:Method)
CN3041115S (en:Method)
CN3041207S (en:Method)
CN3041374S (en:Method)
CN3041383S (en:Method)
CN3042193S (en:Method)
CN3042289S (en:Method)
CN3042424S (en:Method)
CN3042589S (en:Method)
CN3043305S (en:Method)
CN3043413S (en:Method)
CN3043414S (en:Method)
CN3043415S (en:Method)
CN3043416S (en:Method)